BRPI0914927A2 - composto, composição farmacêutica, métodos para inibir a função de fak e de tratamento de um câncer, uso de um composto, e, processo para preparar um composto - Google Patents
composto, composição farmacêutica, métodos para inibir a função de fak e de tratamento de um câncer, uso de um composto, e, processo para preparar um compostoInfo
- Publication number
- BRPI0914927A2 BRPI0914927A2 BRPI0914927A BRPI0914927A BRPI0914927A2 BR PI0914927 A2 BRPI0914927 A2 BR PI0914927A2 BR PI0914927 A BRPI0914927 A BR PI0914927A BR PI0914927 A BRPI0914927 A BR PI0914927A BR PI0914927 A2 BRPI0914927 A2 BR PI0914927A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparing
- methods
- pharmaceutical composition
- cancer treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 3
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7305508P | 2008-06-17 | 2008-06-17 | |
| US61/073055 | 2008-06-17 | ||
| PCT/GB2009/050675 WO2009153589A1 (en) | 2008-06-17 | 2009-06-15 | Pyridine compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0914927A2 true BRPI0914927A2 (pt) | 2017-06-20 |
| BRPI0914927B1 BRPI0914927B1 (pt) | 2020-10-06 |
| BRPI0914927B8 BRPI0914927B8 (pt) | 2021-05-25 |
Family
ID=40896110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0914927A BRPI0914927B8 (pt) | 2008-06-17 | 2009-06-15 | composto, composição farmacêutica e uso de um composto |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8569298B2 (pt) |
| EP (1) | EP2303861B1 (pt) |
| JP (1) | JP5551689B2 (pt) |
| KR (1) | KR101695501B1 (pt) |
| CN (1) | CN102124000B (pt) |
| AU (1) | AU2009261764B2 (pt) |
| BR (1) | BRPI0914927B8 (pt) |
| CA (1) | CA2726508C (pt) |
| CR (1) | CR11854A (pt) |
| DO (1) | DOP2010000390A (pt) |
| EA (1) | EA020807B1 (pt) |
| EC (1) | ECSP10010695A (pt) |
| ES (1) | ES2472323T3 (pt) |
| IL (1) | IL209727A0 (pt) |
| MX (1) | MX2010014057A (pt) |
| WO (1) | WO2009153589A1 (pt) |
| ZA (1) | ZA201100388B (pt) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3384482B2 (ja) | 1997-03-18 | 2003-03-10 | 本田技研工業株式会社 | ピストンリング供給装置 |
| US20140155410A1 (en) * | 2008-10-27 | 2014-06-05 | Glaxosmithkline Llc | Pyrazolylaminopyridines as inhibitors of fak |
| JO3067B1 (ar) * | 2008-10-27 | 2017-03-15 | Glaxosmithkline Llc | بيرميدينات بيرازولو امينو كمثبطات ل fak |
| WO2010068947A2 (en) * | 2008-12-12 | 2010-06-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Nuclear export inhibitors of topoisomerase ii alpha |
| PT2464645T (pt) | 2009-07-27 | 2017-10-11 | Gilead Sciences Inc | Compostos heterocíclicos fusionados como moduladores do canal de iões |
| BR112012029647A2 (pt) | 2010-05-21 | 2016-08-02 | Chemilia Ab | novos derivados de pirimidinas |
| EP2588081A4 (en) | 2010-06-29 | 2014-12-10 | Verastem Inc | ORAL FORMULATION OF CHINESE INHIBITORS |
| MX343894B (es) * | 2010-06-30 | 2016-11-28 | Poniard Pharmaceuticals Inc * | Síntesis y uso de inhibidores de cinasa. |
| WO2012003392A1 (en) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| WO2012103276A1 (en) * | 2011-01-26 | 2012-08-02 | Glaxo Wellcome Manufacturing Pte Ltd | Combinations |
| US20130324532A1 (en) | 2011-02-17 | 2013-12-05 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| AU2012216894B2 (en) | 2011-02-17 | 2016-07-14 | Cancer Therapeutics Crc Pty Limited | Selective FAK inhibitors |
| JP5886411B2 (ja) | 2011-03-24 | 2016-03-16 | ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ | 新規のピリミジン誘導体 |
| AU2012253653A1 (en) | 2011-05-10 | 2013-05-02 | Gilead Sciences, Inc. | Fused heterocyclic compounds as sodium channel modulators |
| TWI622583B (zh) | 2011-07-01 | 2018-05-01 | 基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (pt) | 2011-07-01 | 2018-04-28 | ||
| TW201341367A (zh) | 2012-03-16 | 2013-10-16 | Axikin Pharmaceuticals Inc | ３，５－二胺基吡唑激酶抑制劑 |
| NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
| AP2016009605A0 (en) * | 2014-06-17 | 2016-12-31 | Pfizer | Substituted dihydroisoquinolinone compounds |
| US9442005B2 (en) | 2014-07-30 | 2016-09-13 | Corning Optical Communications LLC | Non-contact methods of measuring insertion loss in optical fiber connectors |
| HUE049801T2 (hu) | 2014-12-23 | 2020-10-28 | Sma Therapeutics Inc | 3,5-diaminopirazol kináz inhibitorok |
| GB201510010D0 (en) | 2015-06-09 | 2015-07-22 | King S College London | PDD and BPD compounds |
| IL256652B2 (en) | 2015-06-29 | 2026-03-01 | Verastem Inc | Dapatinib in combination with an anti-PD1 antibody, anti-PDL1 antibody, or anti-PD1 ligand for use in the treatment of cancer |
| GB201514928D0 (en) | 2015-08-21 | 2015-10-07 | King S College London | PDD compounds |
| US20180339985A1 (en) | 2015-08-21 | 2018-11-29 | Femtogenix Limited | Pdd compounds |
| PE20211754A1 (es) | 2018-02-28 | 2021-09-06 | Basf Se | Uso de compuestos de alcoxi pirazol funcionalizados con n como inhibidores de la nitrificacion |
| WO2019166558A1 (en) | 2018-02-28 | 2019-09-06 | Basf Se | Use of pyrazole propargyl ethers as nitrification inhibitors |
| CN112218658A (zh) | 2018-03-12 | 2021-01-12 | 国家健康科学研究所 | 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途 |
| CN108912095B (zh) * | 2018-08-09 | 2019-08-20 | 广州安岩仁医药科技有限公司 | 苯并咪唑类化合物及其制备方法和应用 |
| JP2022525186A (ja) * | 2019-03-15 | 2022-05-11 | ザ ジェネラル ホスピタル コーポレイション | Ｔｅａｄ転写因子新規小分子阻害剤 |
| EP4045485A1 (en) | 2019-10-18 | 2022-08-24 | The Regents Of The University Of California | 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders |
| US12590298B2 (en) | 2019-10-18 | 2026-03-31 | The Regents Of The University Of California | Ex vivo tumor angiogenesis model |
| EP4341248A1 (en) | 2021-05-21 | 2024-03-27 | Basf Se | Use of an n-functionalized alkoxy pyrazole compound as nitrification inhibitor |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| DE10336184A1 (de) | 2003-08-07 | 2005-02-24 | Bayer Materialscience Ag | Neue Katalysatoren für die selektive Isocyanatdimerisierung |
| TWI378923B (en) * | 2003-08-15 | 2012-12-11 | Novartis Ag | Pyrimidine derivatives |
| US20090118316A1 (en) | 2004-06-21 | 2009-05-07 | Pfzer Inc. | Methods for Augmenting Bone |
| GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| GB0419160D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| CA2590110C (en) | 2004-12-30 | 2014-06-03 | Exelixis, Inc. | Kinase modulators and method of use |
| WO2007063384A2 (en) * | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| RS20080272A (sr) | 2005-12-21 | 2009-07-15 | Pfizer Products Inc., | Derivati pirimidina za tretman neprirodnog rasta ćelija |
| WO2008073687A2 (en) | 2006-12-08 | 2008-06-19 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| CA2681015C (en) * | 2007-03-16 | 2016-06-21 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
| US20100190777A1 (en) * | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US20100317663A1 (en) * | 2008-02-19 | 2010-12-16 | Jerry Leroy Adams | Anilinopyridines as inhibitors of fak |
-
2009
- 2009-06-15 JP JP2011514125A patent/JP5551689B2/ja active Active
- 2009-06-15 AU AU2009261764A patent/AU2009261764B2/en active Active
- 2009-06-15 BR BRPI0914927A patent/BRPI0914927B8/pt active IP Right Grant
- 2009-06-15 ES ES09766150.8T patent/ES2472323T3/es active Active
- 2009-06-15 EP EP09766150.8A patent/EP2303861B1/en active Active
- 2009-06-15 CA CA2726508A patent/CA2726508C/en active Active
- 2009-06-15 KR KR1020117001022A patent/KR101695501B1/ko active Active
- 2009-06-15 US US12/999,025 patent/US8569298B2/en active Active
- 2009-06-15 MX MX2010014057A patent/MX2010014057A/es active IP Right Grant
- 2009-06-15 WO PCT/GB2009/050675 patent/WO2009153589A1/en not_active Ceased
- 2009-06-15 CN CN200980132565.2A patent/CN102124000B/zh active Active
- 2009-06-15 EA EA201100032A patent/EA020807B1/ru not_active IP Right Cessation
-
2010
- 2010-12-02 IL IL209727A patent/IL209727A0/en unknown
- 2010-12-17 DO DO2010000390A patent/DOP2010000390A/es unknown
- 2010-12-17 EC EC2010010695A patent/ECSP10010695A/es unknown
- 2010-12-17 CR CR11854A patent/CR11854A/es not_active Application Discontinuation
-
2011
- 2011-01-14 ZA ZA2011/00388A patent/ZA201100388B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2472323T3 (es) | 2014-06-30 |
| KR101695501B1 (ko) | 2017-01-11 |
| IL209727A0 (en) | 2011-02-28 |
| BRPI0914927B8 (pt) | 2021-05-25 |
| US20110166139A1 (en) | 2011-07-07 |
| EA020807B1 (ru) | 2015-01-30 |
| CA2726508C (en) | 2016-06-07 |
| CN102124000A (zh) | 2011-07-13 |
| CR11854A (es) | 2011-02-25 |
| DOP2010000390A (es) | 2011-01-15 |
| WO2009153589A1 (en) | 2009-12-23 |
| EP2303861B1 (en) | 2014-04-23 |
| KR20110023884A (ko) | 2011-03-08 |
| US8569298B2 (en) | 2013-10-29 |
| AU2009261764A1 (en) | 2009-12-23 |
| BRPI0914927B1 (pt) | 2020-10-06 |
| CN102124000B (zh) | 2014-09-17 |
| HK1155170A1 (en) | 2012-05-11 |
| JP5551689B2 (ja) | 2014-07-16 |
| MX2010014057A (es) | 2011-03-21 |
| AU2009261764B2 (en) | 2013-01-10 |
| ECSP10010695A (es) | 2011-01-31 |
| CA2726508A1 (en) | 2009-12-23 |
| JP2011524411A (ja) | 2011-09-01 |
| EA201100032A1 (ru) | 2012-01-30 |
| ZA201100388B (en) | 2011-10-26 |
| EP2303861A1 (en) | 2011-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0922475A2 (pt) | composto, composição farmacêutica , método para tratar câncer, e, uso de um composto. | |
| BRPI0919488A2 (pt) | composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto | |
| BRPI0915084A2 (pt) | composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer | |
| BRPI0906475A2 (pt) | Compostos, processso para a preparação de um composto, composição farmacêutica e uso de um composto | |
| BRPI0818533A2 (pt) | composto, composição farmacêutica, e, processo para a preparação de um composto | |
| BRPI0908100A2 (pt) | produto combinação, uso de um composto, e, método de tratar câncer | |
| BRPI1006162A2 (pt) | "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto". | |
| BRPI1010937A2 (pt) | composto, uso de um composto, e, método para tratar câncer | |
| BRPI0816331A2 (pt) | Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto. | |
| BRPI0912348A2 (pt) | composto de 3-aminocarbazol, composição farmacêutica, método para preparar um composto de 3-aminocarbazol, uso de um composto de 3-aminocarbazol, e, método para tratar ou prevenir doenças | |
| BRPI0818426A2 (pt) | produto de combinação, uso de um produto de combinação, e, método para tratar câncer | |
| BRPI0813237A2 (pt) | Composto, método para preparar o composto, composição, medicamento, e, uso do composto. | |
| BRPI0812851A2 (pt) | Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto | |
| BRPI0907977A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| BRPI0906786A2 (pt) | Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit. | |
| BR112012029227A2 (pt) | processo para a preparação de um conjunto quiral, composto quiral, composição, composição farmacêutica, uso de uma composição, método de tratamento ou prevenção e uso de um composto | |
| BRPI0815493A2 (pt) | Composto, uso de um composto, composição faramcêutica, método para a terapia de dor, e, processo para preparar um composto. | |
| BRPI0922714A2 (pt) | composto, processo para preparar um compsoto, medicamento, uso de um composto, e, composição farmacêutica | |
| BRPI0906805A2 (pt) | Composto, processo para preparar o enanciômero puro, composição farmacêutica, uso do enanciômero puro, métodos para prevenir ou tratar doença em um animal de sangue quente, e, combinação | |
| BRPI1015983A2 (pt) | composto, uso do composto, método para tratar um paciente, e, composição farmacêutica. | |
| BRPI0811275A2 (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, uso de composto, e, método para tratar doença | |
| BRPI0822946A2 (pt) | Derivado de carboxiamida, processo para preparação de derivado de carboxiamida, composição farmacêutica e uso do derivado de carboxiamida | |
| BRPI0908252A2 (pt) | Processo para preparar um composto, e, uso de um composto | |
| BRPI0907974A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| BRPI0908738A2 (pt) | composto, medicamento, uso de um composto, e, processo para preparar os compostos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |